Nanoparticle-Based Delivery of Tumor Suppressor MicroRNA for Cancer Therapy

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2020 Feb 28

PMID 32102476

Citations 45

Authors

Clodagh P ONeill

Roisin M Dwyer

Affiliations

Soon will be listed here.

Abstract

Improved understanding of microRNA expression and function in cancer has revealed a range of microRNAs that negatively regulate many oncogenic pathways, thus representing potent tumor suppressors. Therapeutic targeting of the expression of these microRNAs to the site of tumors and metastases provides a promising avenue for cancer therapy. To overcome challenges associated with microRNA degradation, transient expression and poor targeting, novel nanoparticles are being developed and employed to shield microRNAs for tumor-targeted delivery. This review focuses on studies describing a variety of both natural and synthetic nanoparticle delivery vehicles that have been engineered for tumor-targeted delivery of tumor suppressor microRNAs in vivo.

Citing Articles

Natural compounds as regulators of miRNAs: exploring a new avenue for treating colorectal cancer.

Doghish A, Mageed S, Mohammed O, Abdel-Reheim M, Zaki M, Mohamed A Funct Integr Genomics. 2025; 25(1):42.

PMID: 39982533 DOI: 10.1007/s10142-025-01547-8.

MicroRNA Nobel Prize: Timely Recognition and High Anticipation of Future Products-A Prospective Analysis.

Niazi S, Magoola M Int J Mol Sci. 2024; 25(23.

PMID: 39684593 PMC: 11641023. DOI: 10.3390/ijms252312883.

Dual Roles of microRNA-122 in Hepatocellular Carcinoma and Breast Cancer Progression and Metastasis: A Comprehensive Review.

Al Ageeli E Curr Issues Mol Biol. 2024; 46(11):11975-11992.

PMID: 39590305 PMC: 11592835. DOI: 10.3390/cimb46110711.

Melanoma Metabolism: Molecular Mechanisms and Therapeutic Implications in Cutaneous Oncology.

J Tan I, Parikh A, Cohen B Cancer Med. 2024; 13(21):e70386.

PMID: 39494561 PMC: 11532834. DOI: 10.1002/cam4.70386.

Advances in nucleic acid therapeutics: structures, delivery systems, and future perspectives in cancer treatment.

Zhang L, Lou W, Wang J Clin Exp Med. 2024; 24(1):200.

PMID: 39196428 PMC: 11358240. DOI: 10.1007/s10238-024-01463-4.

References

Gallardo E, Navarro A, Vinolas N, Marrades R, Diaz T, Gel B . miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis. 2009; 30(11):1903-9. DOI: 10.1093/carcin/bgp219. View

Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D . Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8(4):315-7. DOI: 10.1080/14653240600855905. View

Bhaskaran V, Nowicki M, Idriss M, Jimenez M, Lugli G, Hayes J . The functional synergism of microRNA clustering provides therapeutically relevant epigenetic interference in glioblastoma. Nat Commun. 2019; 10(1):442. PMC: 6347618. DOI: 10.1038/s41467-019-08390-z. View

Thery C, Witwer K, Aikawa E, Alcaraz M, Anderson J, Andriantsitohaina R . Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2019; 7(1):1535750. PMC: 6322352. DOI: 10.1080/20013078.2018.1535750. View

Crawford M, Batte K, Yu L, Wu X, Nuovo G, Marsh C . MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer. Biochem Biophys Res Commun. 2009; 388(3):483-9. PMC: 2824514. DOI: 10.1016/j.bbrc.2009.07.143. View

Comella P, Casaretti R, Sandomenico C, Avallone A, Franco L . Role of oxaliplatin in the treatment of colorectal cancer. Ther Clin Risk Manag. 2009; 5(1):229-38. PMC: 2697505. DOI: 10.2147/tcrm.s3583. View

van Zandwijk N, Pavlakis N, Kao S, Linton A, Boyer M, Clarke S . Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol. 2017; 18(10):1386-1396. DOI: 10.1016/S1470-2045(17)30621-6. View

Gokita K, Inoue J, Ishihara H, Kojima K, Inazawa J . Therapeutic Potential of LNP-Mediated Delivery of miR-634 for Cancer Therapy. Mol Ther Nucleic Acids. 2019; 19:330-338. PMC: 6938807. DOI: 10.1016/j.omtn.2019.10.045. View

Macfarlane L, Murphy P . MicroRNA: Biogenesis, Function and Role in Cancer. Curr Genomics. 2011; 11(7):537-61. PMC: 3048316. DOI: 10.2174/138920210793175895. View

10.

Gilligan K, Dwyer R . Extracellular Vesicles for Cancer Therapy: Impact of Host Immune Response. Cells. 2020; 9(1). PMC: 7016566. DOI: 10.3390/cells9010224. View

11.

Sun C, Zhang L, Li G, Li S, Chen Z, Fu Y . The lncRNA PDIA3P Interacts with miR-185-5p to Modulate Oral Squamous Cell Carcinoma Progression by Targeting Cyclin D2. Mol Ther Nucleic Acids. 2017; 9:100-110. PMC: 5626923. DOI: 10.1016/j.omtn.2017.08.015. View

12.

Thammaiah C, Jayaram S . Role of family microRNA in breast cancer. Noncoding RNA Res. 2018; 1(1):77-82. PMC: 6096426. DOI: 10.1016/j.ncrna.2016.10.003. View

13.

Kozomara A, Birgaoanu M, Griffiths-Jones S . miRBase: from microRNA sequences to function. Nucleic Acids Res. 2018; 47(D1):D155-D162. PMC: 6323917. DOI: 10.1093/nar/gky1141. View

14.

Bail S, Swerdel M, Liu H, Jiao X, Goff L, Hart R . Differential regulation of microRNA stability. RNA. 2010; 16(5):1032-9. PMC: 2856875. DOI: 10.1261/rna.1851510. View

15.

Wu Y, Crawford M, Yu B, Mao Y, Nana-Sinkam S, Lee L . MicroRNA delivery by cationic lipoplexes for lung cancer therapy. Mol Pharm. 2011; 8(4):1381-9. PMC: 4136514. DOI: 10.1021/mp2002076. View

16.

Thery C, Zitvogel L, Amigorena S . Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002; 2(8):569-79. DOI: 10.1038/nri855. View

17.

Moro M, Di Paolo D, Milione M, Centonze G, Bornaghi V, Borzi C . Coated cationic lipid-nanoparticles entrapping miR-660 inhibit tumor growth in patient-derived xenografts lung cancer models. J Control Release. 2019; 308:44-56. DOI: 10.1016/j.jconrel.2019.07.006. View

18.

de Araujo R, da Silva Santos S, Ferreira E, Giarolla J . New Advances in General Biomedical Applications of PAMAM Dendrimers. Molecules. 2018; 23(11). PMC: 6278347. DOI: 10.3390/molecules23112849. View

19.

Kumar A, Nayak S, Pathak P, Purkait S, Malgulawar P, Sharma M . Identification of miR-379/miR-656 (C14MC) cluster downregulation and associated epigenetic and transcription regulatory mechanism in oligodendrogliomas. J Neurooncol. 2018; 139(1):23-31. PMC: 6061222. DOI: 10.1007/s11060-018-2840-6. View

20.

Wu W, Hu Q, Wang M, Shao S, Zhao X, Bai H . A PEGylated megamer-based microRNA delivery system activatable by stepwise microenvironment stimulation. Chem Commun (Camb). 2019; 55(63):9363-9366. DOI: 10.1039/c9cc03846a. View